Source: GlobeNewswire — 2026-08-03
Summary
CMS has approved a New Technology Add-on Payment (NTAP) of up to $2,171 for Ceribell's Delirium Monitor, an FDA-cleared system that continuously analyzes EEG segments at the bedside to flag delirium-related brain activity in critically ill patients. The payment takes effect October 1, 2026, and rides on top of Ceribell's existing FDA-cleared seizure and status epilepticus detection technology, giving hospitals Medicare reimbursement for a second AI-driven use of the same point-of-care EEG hardware. The Delirium Monitor received FDA 510(k) clearance in December 2025, the first clearance of its kind for aiding delirium screening and monitoring.
Key Takeaways
- CMS's NTAP pays hospitals up to $2,171 per eligible Medicare patient for use of the Delirium Monitor, effective October 1, 2026 — a direct financial incentive for ICUs and EDs to adopt the technology rather than a research grant or pilot subsidy.
- The device works by continuously reading EEG segments at the bedside and using an algorithm to identify patterns associated with delirium, rather than relying on periodic bedside screening checklists alone.
- The delirium-detection algorithm was validated against EEG data and clinical assessments from a prospective study of 225 adults in critical care settings, per the FDA clearance.
- This is Ceribell's second NTAP-covered indication on the same platform — the company already holds Medicare add-on payment coverage for its nonconvulsive seizure and electrographic status epilepticus detection — meaning one bedside EEG device now supports two separately reimbursed AI use cases.
- Delirium in ICU patients is common and costly to manage, and unlike seizures it's often missed by intermittent clinical assessment, so continuous automated monitoring addresses a real gap in current bedside practice rather than duplicating existing screening tools.